Shares of Celldex Therapeutics (CLDX) have gained 5.2% over the past four weeks to close the last trading session at 41.21,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof69.14 indicates a potential upside of 67.8%.The mean estimate comprises seven short-term price targets with a standard deviation of 20.15.Whilethelowestestimateof27 indicates a 34.5% decline from the ...